You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study
|
|---|---|
| Published in |
BMC Neurology, October 2013
|
| DOI | 10.1186/1471-2377-13-138 |
| Pubmed ID | |
| Authors |
Neetu Agashivala, Ning Wu, Safiya Abouzaid, You Wu, Edward Kim, Luke Boulanger, David W Brandes |
| Abstract |
Adherence to disease-modifying therapies (DMTs) results in the reduction of the number and severity of relapses and delays the progression of multiple sclerosis (MS). Patients with lower adherence rates experience more inpatient visits and higher MS-related medical costs. Fingolimod, the first oral DMT approved by the US Food and Drug Administration, may improve the access and compliance to MS treatment when compared to injectable DMTs. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Egypt | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 67% |
| Members of the public | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 97 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Portugal | 1 | 1% |
| Uruguay | 1 | 1% |
| Brazil | 1 | 1% |
| Spain | 1 | 1% |
| United States | 1 | 1% |
| Unknown | 92 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 17 | 18% |
| Student > Master | 12 | 12% |
| Student > Bachelor | 12 | 12% |
| Student > Ph. D. Student | 11 | 11% |
| Other | 10 | 10% |
| Other | 11 | 11% |
| Unknown | 24 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 30 | 31% |
| Nursing and Health Professions | 7 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 7% |
| Agricultural and Biological Sciences | 6 | 6% |
| Neuroscience | 3 | 3% |
| Other | 16 | 16% |
| Unknown | 28 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 November 2013.
All research outputs
#2,858,282
of 22,725,280 outputs
Outputs from BMC Neurology
#311
of 2,424 outputs
Outputs of similar age
#27,378
of 207,659 outputs
Outputs of similar age from BMC Neurology
#10
of 68 outputs
Altmetric has tracked 22,725,280 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,424 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 207,659 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 68 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.